Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Saade

Pediatrics Marietta, GA Medical Doctor

NPI 1881668580 CMS profile 130280

3707 Largent Way Nw, Marietta, GA 30064

Open in the dashboard

General payments

$3,196

164 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Saade of Marietta, GA is reported in the CMS Open Payments database as having received $3,196 across 164 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $729 40
2024 General $763 32
2023 General $613 34
2022 General $512 29
2021 General $172 9
2020 General $230 8
2019 General $179 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Saade
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Daniel Saade were reported at $729. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Daniel Saade Pediatrics median Middle half National median
2019 $179 $86 $31–$183 $163
2020 $230 $49 $22–$110 $114
2021 $172 $68 $27–$158 $132
2022 $512 $77 $30–$173 $149
2023 $613 $88 $33–$190 $160
2024 $763 $94 $34–$206 $164
2025 $729 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ironshore Pharmaceuticals Inc. $711 29 payments
  2. Supernus Pharmaceuticals, Inc. $588 28 payments
  3. Corium, Inc. $519 39 payments
  4. Collegium Pharmaceutical, Inc. $282 8 payments
  5. Tris Pharma Inc $242 12 payments
  6. Neos Therapeutics, LP $198 11 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $125 8 payments
  8. Novo Nordisk Inc $107 6 payments
  9. Dynavax Technologies Corporation $99 4 payments
  10. GlaxoSmithKline, LLC. $80 5 payments
  11. Other $246 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,196 164 payments
Products named General payments · program years 2019–2025
  1. Azstarys $519 39 payments
  2. Qelbree $511 23 payments
  3. JORNAY PM Central Nervous System Stimulant $354 16 payments
  4. JORNAY PM Central Nervous Stimulant ADHD $339 12 payments
  5. Jornay PM Adhd $282 8 payments
  6. Dyanavel XR $146 7 payments
  7. VYVANSE $119 7 payments
  8. Adzenys XR-ODT $109 6 payments
  9. COTEMPLA XR-ODT $108 6 payments
  10. Heplisav-B $99 4 payments
  11. Other $1,121 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

164 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record